The determination of 4-amino-1-hydroxybutane-1,1-diphosphonic acid monosodium salt trihydrate in pharmaceutical dosage forms by high-performance liquid chromatography.
A rapid, sensitive and specific high-performance liquid chromatographic (HPLC) assay is reported for the determination of 4-amino-1-hydroxybutane-1, 1-diphosphonic acid (AHBuDP) monosodium salt trihydrate, a new inhibitor of bone resorption. The compound does not demonstrate any intrinsic UV properties and thus pre-column derivatization of the primary amino group of the drug with 9-fluorenylmethyl chloroformate (FMOC) at pH 9 in the presence of sodium citrate is required to facilitate UV detection of the analyte. Excess derivatization reagent is extracted with methylene chloride and an aliquot of the aqueous portion is assayed on a polymeric phase (Hamilton PRP-1) at 35 degrees C by reversed-phase HPLC. A mobile phase of 0.05 M citrate and 0.05 M phosphate buffer (pH 8.0)-acetonitrile-methanol (75:20:5, v/v/v) is utilized with UV detection at 266 nm. Application of the method to the analysis of AHBuDP in I.V. solution, tablet and capsule formulations is presented.
De Marco
J D
JD
Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.
Biffar
S E
SE
Reed
D G
DG
Brooks
M A
MA
D019386:Alendronate; D002214:Capsules; D002851:Chromatography, High Pressure Liquid; D004164:Diphosphonates / Q000032:analysis* / Q000737:chemistry; D007202:Indicators and Reagents; D011137:Polystyrenes; D012995:Solubility; D012996:Solutions; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets; D013696:Temperature
D002214:Capsules; D004164:Diphosphonates; D007202:Indicators and Reagents; D011137:Polystyrenes; D012996:Solutions; D013607:Tablets; C003771:Amberlite XAD-2 resin; D019386:Alendronate